Xolair, which contains omalizumab, is indicated for diseases such as severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria.
Christine Fox, who most recently served as global president of gene therapies at Novartis, will head Teva’s U.S. commercial business, succeeding Sven Dethlefs.